Dose-escalated simultaneous integrated boost radiotherapy may increase ipsilateral breast tumor relapse rates
1. 5-year ipsilateral breast tumor relapse rates for test group 1 were non-inferior to the control group. However, noninferiority was ...
Tag: breast cancer recurrence
Temporary interruption of endocrine therapy in women with endocrine-responsive breast cancer did not affect cancer outcomes
1. The 3-year incidence of breast cancer in the study group was 8.9% compared to 9.2% in the control group ...
No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
1. Disease-free survival did not differ significantly between patient groups and overall survival at 3 years was the same for ...
Adjuvant celecoxib not associated with improved disease-free survival in patients with ERBB2-negative breast cancer
1. The study found no evidence of benefit to disease-free survival when 400 mg of celecoxib was administered once daily ...
Tamoxifen decreases recurrence rates at 25 years in lymph node-negative estrogen-receptor-positive and Erb-B2 Receptor Tyrosine Kinase 2-negative breast cancer
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone ...
#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women
Click to read the study in Clinical Cancer Research.